Cell Therapeutics (CTIC) 2.23 $CTIC
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Here Is Why We Believe CTI BioPharma's PERSIST-1 Trial Will Be Successful
Probio Invest - at Seeking Alpha - Tue Feb 10, 10:23AM CST
BAX: 70.39 (+0.31), INCY: 75.94 (+0.28), CTIC: 2.23 (-0.02), SNY: 49.42 (+0.82)
CTI BioPharma Announces Independent DMC Recommendation to Continue GOG-0212 Phase 3 Study of OPAXIO(TM) as Maintenance Therapy in Ovarian Cancer, an NRG Oncology/GOG Study
PR Newswire - Tue Feb 03, 12:30AM CST
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group, now part of NRG Oncology, informed CTI BioPharma that an independent Data Monitoring Committee (DMC) recommended continuation of the GOG-0212 Phase 3 clinical study of OPAXIO(TM) (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a second of four planned interim analyses for survival and futility. CTI BioPharma remains blinded to the interim analysis results. GOG-0212 is the largest maintenance study in this setting, having enrolled 1,150 patients.
CTIC: 2.23 (-0.02)
Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?
at The Street - Fri Jan 30, 7:39AM CST
The F-R Rule has a perfect record predicting the failure of phase III cancer trials when the company running the trial has a market cap of $300 million or less.
INCY: 75.94 (+0.28), CTIC: 2.23 (-0.02)
Market Momentum on Biotech Stocks - CTI BioPharma, Keryx Biopharma, Intrexon, Catalyst Pharma Partners, and iBio
PR Newswire - Wed Jan 14, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Intrexon Corporation (NYSE: XON), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and iBio Inc. (NYSE MKT: IBIO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, January 13, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 17,613.68, down 0.15% and the NASDAQ Composite closed at 4,661.50, down 0.07%. The S&P 500 finished the session 0.26% lower at 2,023.03. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 808.73, down 0.49%, whereas the index has gained 13.71% in the previous three months. Register for your complimentary reports on these five stocks at:
CPRX: 3.36 (-0.10), XON: 39.30 (+1.05), IBIO: 0.90 (+0.36), CTIC: 2.23 (-0.02), KERX: 11.63 (-0.60)
Traders Get Bullish on Shares of Cell Therapeutics, Shares Up 7.8% (CTIC)
Comtex SmarTrend(R) - Tue Jan 13, 10:29AM CST
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 7.8% to $2.48 on 2.5x average daily volume. Cell Therapeutics has traded 3.2 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has outperformed the Dow (7.8% to the Dow's 1.4%) and outperformed the S&P 500 (7.8% to the S&P's 1.3%) during today's trading.
CTIC: 2.23 (-0.02)
Premarket Gainers/Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 8:24AM CST
ANV: 0.97 (-0.03), ALX: 453.22 (-6.93), PCYC: 163.28 (+0.23), NLST: 1.86 (unch), ECOM: 9.69 (+0.63), VLCCF: 4.15 (-0.06), PHMD: 1.68 (+0.04), BNCL: 11.54 (-0.02), GURE: 1.64 (-0.04), CTIC: 2.23 (-0.02), AUY: 4.13 (+0.13), ATRS: 2.45 (+0.05)
CTI Bio up on increased revenue guidance
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 7:04AM CST
CTIC: 2.23 (-0.02)
CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
PR Newswire - Mon Jan 12, 12:30AM CST
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) announced today the appointment of Alan K. Burnett, M.D., to serve as the strategic leader for myeloid development. Dr. Burnett most recently served as Professor and Head of the Department of Haematology in the Institute of Cancer and Genetics at Cardiff University and is highly regarded internationally for his work in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Dr. Burnett will be responsible for creating and implementing the strategic development program for CTI BioPharma's compounds in myeloid malignancies with a major focus on supplementing CTI BioPharma's current late-stage development programs in chronic myeloproliferative diseases and international development programs in other myeloid malignancies such as acute myeloid leukemias and myelodysplasia. Dr. Burnett will also help to identify promising earlier stage targets and therapeutics for potential development collaborations.
CTIC: 2.23 (-0.02)
Insider Trading Alert - IRET, CTIC And RKUS Traded By Insiders
at The Street - Thu Jan 08, 9:30AM CST
Stocks with insider trader activity include IRET, CTIC and RKUS
IRET: 7.75 (+0.09), CTIC: 2.23 (-0.02), RKUS: 10.53 (-0.12)
CTI BioPharma Announces 2015 Outlook and Recent Drug Portfolio Progress
PR Newswire - Thu Jan 08, 12:30AM CST
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced an overview of recent progress for its drug portfolio in addition to several anticipated key objectives for 2015.
CTIC: 2.23 (-0.02)
First Week of CTIC February 2015 Options Trading
StockOptionsChannel.com - Wed Dec 24, 11:46AM CST
Investors in CTI BioPharma Corp saw new options become available this week, for the February 2015 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new February 2015 contracts and...
CTIC: 2.23 (-0.02)
Insider Trading Alert - CTIC, FXCM And CRM Traded By Insiders
at The Street - Mon Dec 22, 9:45AM CST
Stocks with insider trader activity include CTIC, FXCM and CRM
FXCM: 2.21 (-0.01), CTIC: 2.23 (-0.02), CRM: 62.85 (+1.59)
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
at The Street - Wed Dec 17, 8:20AM CST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), NBIX: 37.22 (+0.27), GILD: 101.90 (+1.10), ARWR: 6.77 (+0.21), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), CTIC: 2.23 (-0.02), CEMP: 27.68 (+1.25), BMY: 60.04 (+0.56)
Where Are They Now? A Look Back at the Best & Worst Biotech CEOs
at The Street - Tue Dec 16, 10:20AM CST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
VRTX: 113.66 (+4.03), MYGN: 34.03 (+0.40), DNDN: 0.13 (-0.02), CTIC: 2.23 (-0.02), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)
Bone Degeneration - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/mtq3mr/bone_degeneration) has announced the addition of the "Bone Degeneration - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bone Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bone Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alethia Biotherapeutics Inc. - Calzada Limited - CTI BioPharma Corp. - GliaMed, Inc. - Histocell S.L. - TechnoPhage SA - TissueGene, Inc. For more information visit http://www.researchandmarkets.com/research/mt...generation
CTIC: 2.23 (-0.02)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 0.45 (+0.06), GILD: 101.90 (+1.10), GERN: 3.03 (unch), ONTX: 2.27 (-0.02), CTIC: 2.23 (-0.02), BMY: 60.04 (+0.56), STML: 14.07 (-0.10), NVS: 102.20 (-0.17), MEIP: 5.00 (-0.04), CELGZ: 3.17 (-0.04), XLRN: 38.02 (+0.07)
CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells
PR Newswire - Tue Dec 09, 12:30AM CST
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays. The findings from this study were presented by Dr. Ceri Marrin, Consultant Haematologist, University Hospital of Wales at Cardiff University, during an oral presentation at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition held December 6-9 in San Francisco, CA.
CTIC: 2.23 (-0.02)
Insider Trading Alert - CSU, IRBT And CTIC Traded By Insiders
at The Street - Mon Dec 08, 9:45AM CST
Stocks with insider trader activity include CSU, IRBT and CTIC
CSU: 24.59 (+0.03), CTIC: 2.23 (-0.02), IRBT: 31.16 (+0.18)
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/jtddt5/postpolycythemia) has announced the addition of the "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AstraZeneca - Gilead Sciences - Novartis - Nippon Shinyaku - CTI BioPharma - Incyte - Italfarmaco - Promedior - Pharma Mar For more information visit http://www.researchandmarkets.com/research/jt...lycythemia
GILD: 101.90 (+1.10), CTIC: 2.23 (-0.02), NVS: 102.20 (-0.17)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Here Is Why We Believe CTI BioPharma's PERSIST-1 Trial Will Be Successful
Probio Invest - at Seeking Alpha - Tue Feb 10, 10:23AM CST
BAX: 70.39 (+0.31), INCY: 75.94 (+0.28), CTIC: 2.23 (-0.02), SNY: 49.42 (+0.82)
CTI BioPharma Announces Independent DMC Recommendation to Continue GOG-0212 Phase 3 Study of OPAXIO(TM) as Maintenance Therapy in Ovarian Cancer, an NRG Oncology/GOG Study
PR Newswire - Tue Feb 03, 12:30AM CST
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group, now part of NRG Oncology, informed CTI BioPharma that an independent Data Monitoring Committee (DMC) recommended continuation of the GOG-0212 Phase 3 clinical study of OPAXIO(TM) (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a second of four planned interim analyses for survival and futility. CTI BioPharma remains blinded to the interim analysis results. GOG-0212 is the largest maintenance study in this setting, having enrolled 1,150 patients.
CTIC: 2.23 (-0.02)
Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?
at The Street - Fri Jan 30, 7:39AM CST
The F-R Rule has a perfect record predicting the failure of phase III cancer trials when the company running the trial has a market cap of $300 million or less.
INCY: 75.94 (+0.28), CTIC: 2.23 (-0.02)
Market Momentum on Biotech Stocks - CTI BioPharma, Keryx Biopharma, Intrexon, Catalyst Pharma Partners, and iBio
PR Newswire - Wed Jan 14, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Intrexon Corporation (NYSE: XON), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and iBio Inc. (NYSE MKT: IBIO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, January 13, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 17,613.68, down 0.15% and the NASDAQ Composite closed at 4,661.50, down 0.07%. The S&P 500 finished the session 0.26% lower at 2,023.03. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 808.73, down 0.49%, whereas the index has gained 13.71% in the previous three months. Register for your complimentary reports on these five stocks at:
CPRX: 3.36 (-0.10), XON: 39.30 (+1.05), IBIO: 0.90 (+0.36), CTIC: 2.23 (-0.02), KERX: 11.63 (-0.60)
Traders Get Bullish on Shares of Cell Therapeutics, Shares Up 7.8% (CTIC)
Comtex SmarTrend(R) - Tue Jan 13, 10:29AM CST
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 7.8% to $2.48 on 2.5x average daily volume. Cell Therapeutics has traded 3.2 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has outperformed the Dow (7.8% to the Dow's 1.4%) and outperformed the S&P 500 (7.8% to the S&P's 1.3%) during today's trading.
CTIC: 2.23 (-0.02)
Premarket Gainers/Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 8:24AM CST
ANV: 0.97 (-0.03), ALX: 453.22 (-6.93), PCYC: 163.28 (+0.23), NLST: 1.86 (unch), ECOM: 9.69 (+0.63), VLCCF: 4.15 (-0.06), PHMD: 1.68 (+0.04), BNCL: 11.54 (-0.02), GURE: 1.64 (-0.04), CTIC: 2.23 (-0.02), AUY: 4.13 (+0.13), ATRS: 2.45 (+0.05)
CTI Bio up on increased revenue guidance
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 7:04AM CST
CTIC: 2.23 (-0.02)
CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
PR Newswire - Mon Jan 12, 12:30AM CST
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) announced today the appointment of Alan K. Burnett, M.D., to serve as the strategic leader for myeloid development. Dr. Burnett most recently served as Professor and Head of the Department of Haematology in the Institute of Cancer and Genetics at Cardiff University and is highly regarded internationally for his work in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Dr. Burnett will be responsible for creating and implementing the strategic development program for CTI BioPharma's compounds in myeloid malignancies with a major focus on supplementing CTI BioPharma's current late-stage development programs in chronic myeloproliferative diseases and international development programs in other myeloid malignancies such as acute myeloid leukemias and myelodysplasia. Dr. Burnett will also help to identify promising earlier stage targets and therapeutics for potential development collaborations.
CTIC: 2.23 (-0.02)
Insider Trading Alert - IRET, CTIC And RKUS Traded By Insiders
at The Street - Thu Jan 08, 9:30AM CST
Stocks with insider trader activity include IRET, CTIC and RKUS
IRET: 7.75 (+0.09), CTIC: 2.23 (-0.02), RKUS: 10.53 (-0.12)
CTI BioPharma Announces 2015 Outlook and Recent Drug Portfolio Progress
PR Newswire - Thu Jan 08, 12:30AM CST
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced an overview of recent progress for its drug portfolio in addition to several anticipated key objectives for 2015.
CTIC: 2.23 (-0.02)
First Week of CTIC February 2015 Options Trading
StockOptionsChannel.com - Wed Dec 24, 11:46AM CST
Investors in CTI BioPharma Corp saw new options become available this week, for the February 2015 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new February 2015 contracts and...
CTIC: 2.23 (-0.02)
Insider Trading Alert - CTIC, FXCM And CRM Traded By Insiders
at The Street - Mon Dec 22, 9:45AM CST
Stocks with insider trader activity include CTIC, FXCM and CRM
FXCM: 2.21 (-0.01), CTIC: 2.23 (-0.02), CRM: 62.85 (+1.59)
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
at The Street - Wed Dec 17, 8:20AM CST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), NBIX: 37.22 (+0.27), GILD: 101.90 (+1.10), ARWR: 6.77 (+0.21), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), CTIC: 2.23 (-0.02), CEMP: 27.68 (+1.25), BMY: 60.04 (+0.56)
Where Are They Now? A Look Back at the Best & Worst Biotech CEOs
at The Street - Tue Dec 16, 10:20AM CST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
VRTX: 113.66 (+4.03), MYGN: 34.03 (+0.40), DNDN: 0.13 (-0.02), CTIC: 2.23 (-0.02), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)
Bone Degeneration - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/mtq3mr/bone_degeneration) has announced the addition of the "Bone Degeneration - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bone Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bone Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alethia Biotherapeutics Inc. - Calzada Limited - CTI BioPharma Corp. - GliaMed, Inc. - Histocell S.L. - TechnoPhage SA - TissueGene, Inc. For more information visit http://www.researchandmarkets.com/research/mt...generation
CTIC: 2.23 (-0.02)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 0.45 (+0.06), GILD: 101.90 (+1.10), GERN: 3.03 (unch), ONTX: 2.27 (-0.02), CTIC: 2.23 (-0.02), BMY: 60.04 (+0.56), STML: 14.07 (-0.10), NVS: 102.20 (-0.17), MEIP: 5.00 (-0.04), CELGZ: 3.17 (-0.04), XLRN: 38.02 (+0.07)
CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells
PR Newswire - Tue Dec 09, 12:30AM CST
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays. The findings from this study were presented by Dr. Ceri Marrin, Consultant Haematologist, University Hospital of Wales at Cardiff University, during an oral presentation at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition held December 6-9 in San Francisco, CA.
CTIC: 2.23 (-0.02)
Insider Trading Alert - CSU, IRBT And CTIC Traded By Insiders
at The Street - Mon Dec 08, 9:45AM CST
Stocks with insider trader activity include CSU, IRBT and CTIC
CSU: 24.59 (+0.03), CTIC: 2.23 (-0.02), IRBT: 31.16 (+0.18)
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/jtddt5/postpolycythemia) has announced the addition of the "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AstraZeneca - Gilead Sciences - Novartis - Nippon Shinyaku - CTI BioPharma - Incyte - Italfarmaco - Promedior - Pharma Mar For more information visit http://www.researchandmarkets.com/research/jt...lycythemia
GILD: 101.90 (+1.10), CTIC: 2.23 (-0.02), NVS: 102.20 (-0.17)
